TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Tuberculosis
Interventions
DRUG

Moxifloxacin

400 mg po qd 5/7 days per week

DRUG

Isoniazid

isoniazid 300 mg po qd 5/7 days per week

Trial Locations (8)

21231

Johns Hopkins University, Baltimore

27710

Duke University Medical Center, Durham

76104

University of North Texas Health Science Center, Fort Worth

77030

Houston Veterans Administration Medical Center, Houston

78284

Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio

90033

University of Southern California Medical Center, Los Angeles

V5Z 1L8

University of British Columbia, Vancouver

Unknown

Makerere University Medical School, Kampala

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

US Department of Veterans Affairs

FED

collaborator

Bayer

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Centers for Disease Control and Prevention

FED

NCT00164463 - TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment | Biotech Hunter | Biotech Hunter